Xcout Intel
MinervaX
MinervaX is a privately held biotechnology company headquartered in Copenhagen, Denmark, pursuing the development of a novel maternal prophylactic vaccine for the prevention of Group B Streptococcus disease.
Subscribe to see MinervaX’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
MinervaX at a glance
MinervaX is a drug discovery company headquartered in Denmark. Xcout tracks 10 named people at MinervaX, including Veronica Gambillara Fonck (Chair of the Board).
MinervaX leadership
- Veronica Gambillara FonckChair of the Board
- Bita SehatBoard member
- Christopher GagliardiBoard member
- Emmanuelle CoutanceauBoard member
- Kabeer AzizBoard member
- Patrik SobockiBoard member
4 more named people on record for MinervaX, with roles, board committees and tenure — see the full roster →
MinervaX competitors
A few of MinervaX's closest competitors — see the full list of competitors and alternatives →
Smartbax is a biotechnology startup founded in Munich, Germany, in 2021, dedicated to developing innovative next-generation antibiotics to combat the rising threat of multidrug-resistant bacteria.
ApoGlyx is a Swedish life science company located in Lund that focuses on developing innovative medicines for acute systemic inflammatory diseases such as sepsis and acute pancreatitis.
ReproNovo is a biopharmaceutical company dedicated to developing innovative treatments for reproductive medicine. Headquartered in Lausanne, Switzerland, the company maintains primary development operations in Copenhagen, Denmark, and an additional site in Barcelona, Spain. It is backed by prominent life sciences investors.
Glycomine, Inc. is a biotherapeutics company focused on developing replacement therapies and treatments for serious rare genetic diseases, operating out of major life science hubs in San Francisco and Boston.
Pieris Pharmaceuticals, Inc. is a clinical-stage biotechnology company headquartered in Boston, Massachusetts. The company discovers and develops Anticalin-based drugs designed to address significant medical needs.
Get MinervaX's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on MinervaX in Xcout Intel
- 10 named people with titles, LinkedIn and board committees
- The full competitor set, tracking, exports and API access